← Back to Search

Cancer Vaccine

Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation for Risk Reduction

Phase 1
Waitlist Available
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately six months
Awards & highlights

Summary

This trial is testing a new vaccine to prevent serious Salmonella infections. It aims to see if the vaccine is safe and how well it helps the immune system fight the bacteria. The study focuses on people at risk of severe Salmonella disease. The recent emergence of multi-drug-resistant Salmonella strains highlights the need for better preventive measures, including vaccination.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately six months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately six months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Frequency and Severity of Solicited Local and Systemic Adverse Events (AEs)
Frequency and Severity of Unsolicited AEs and Serious Adverse Events (SAEs)
Proportion of Responders

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Group C: Dilutional Half-Strength FormulationExperimental Treatment1 Intervention
Individuals receive one dose of dilutional half-strength Trivalent Salmonella Conjugate Vaccine (TSCV). Subsequent blood samples are taken for safety and immunological testing.
Group II: Group B: Half-Strength FormulationExperimental Treatment1 Intervention
Individuals receive one dose of half-strength Trivalent Salmonella Conjugate Vaccine (TSCV). Subsequent blood samples are taken for safety and immunological testing.
Group III: Group A: Full-Strength FormulationExperimental Treatment1 Intervention
Individuals receive one dose of full-strength Trivalent Salmonella Conjugate Vaccine (TSCV). Subsequent blood samples are taken for safety and immunological testing.
Group IV: Group D: PlaceboPlacebo Group1 Intervention
Individuals receive one dose of placebo. Subsequent blood samples are taken for safety and immunological testing.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation
2022
Completed Phase 1
~90
Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation
2022
Completed Phase 1
~90
Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation
2022
Completed Phase 1
~90

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
705 Previous Clinical Trials
378,378 Total Patients Enrolled
2 Trials studying Risk Reduction
246 Patients Enrolled for Risk Reduction
Myron M Levine, MD, DTPHStudy DirectorUniversity of Maryland, Baltimore
2 Previous Clinical Trials
4,284 Total Patients Enrolled
~27 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top